PMID- 12689659
OWN - NLM
STAT- MEDLINE
DCOM- 20040107
LR  - 20191107
IS  - 1567-5769 (Print)
IS  - 1567-5769 (Linking)
VI  - 3
IP  - 4
DP  - 2003 Apr
TI  - Interleukin 18 and transforming growth factor beta1 in the serum of patients with 
      Graves' ophthalmopathy treated with corticosteroids.
PG  - 549-52
AB  - Interleukin-18 (IL-18), a novel cytokine of the IL-1 family, and TGFbeta1 have 
      been lately identified in several thyroid autoimmune diseases. The aim of this 
      study was to estimate the influence of corticosteroids on serum IL-18 and 
      TGFbeta1 in Graves' ophthalmopathy (GO) patients and to assess their potential as 
      a guideline of immunosuppressive therapy. The study was carried out in three 
      groups of subjects: (1). 17 patients with clinical symptoms of ophthalmopathy 
      (GO) that underwent corticosteroid therapy consisting of intravenous 
      methylprednisolone (MP) infusions and subsequent treatment with oral prednisone 
      (P); (2). 14 patients with euthyroid Graves' disease (Gd) without symptoms of 
      ophthalmopathy; (3). 12 healthy volunteers age- and sex-matched to groups 1 and 
      2. The serum levels of IL-18 and TGF beta1 were determined by the ELISA method. 
      Thyroid receptor antibodies (TRAB) were estimated by the RIA method. Levels of 
      IL-18 were significantly higher in both GO [340+/-109 pg/ml (p<0.02)] and Gd 
      individuals [308+/-89 pg/ml (p<0.05)] as compared to the control group (238+/-88 
      pg/ml). There were no significant differences in TGFbeta1 concentrations between 
      studied groups. TRAB values were significantly increased in both GO (p<0.001) and 
      Gd individuals (p<0.001) as compared to the controls. In coticosteroid-responsive 
      patients we have found a significant decrease in IL-18 serum concentration as 
      compared to the pretreatment values. We did not find any correlation between 
      IL-18 or TGFbeta1 and TRAB, duration of GO, clinical activity score (CAS) or 
      proptosis. Our results suggest that efficient corticosteroid therapy in patients 
      with Graves' ophthalmopathy may be related to its influence on systemic IL-18.
FAU - Mysliwiec, Janusz
AU  - Mysliwiec J
AD  - Department of Endocrinology, Medical University of Bialzystok, M C 
      Sklodowskiej-Curie 24 a, 15-267 Bialzystok, Poland. mysjan@poczta.onet.pl
FAU - Kretowski, Adam
AU  - Kretowski A
FAU - Stepien, Agnieszka
AU  - Stepien A
FAU - Mironczuk, Katarzyna
AU  - Mironczuk K
FAU - Kinalska, Ida
AU  - Kinalska I
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Immunoglobulins, Thyroid-Stimulating)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Interleukin-18)
RN  - 0 (Transforming Growth Factor beta)
RN  - VB0R961HZT (Prednisone)
RN  - X4W7ZR7023 (Methylprednisolone)
SB  - IM
MH  - Adrenal Cortex Hormones/*therapeutic use
MH  - Female
MH  - Graves Disease/*blood/drug therapy/immunology
MH  - Humans
MH  - Immunoglobulins, Thyroid-Stimulating/blood
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Interleukin-18/*blood
MH  - Male
MH  - Methylprednisolone/therapeutic use
MH  - Middle Aged
MH  - Prednisone/therapeutic use
MH  - Transforming Growth Factor beta/*blood
EDAT- 2003/04/12 05:00
MHDA- 2004/01/08 05:00
CRDT- 2003/04/12 05:00
PHST- 2003/04/12 05:00 [pubmed]
PHST- 2004/01/08 05:00 [medline]
PHST- 2003/04/12 05:00 [entrez]
AID - S1567576903000456 [pii]
AID - 10.1016/s1567-5769(03)00045-6 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2003 Apr;3(4):549-52. doi: 10.1016/s1567-5769(03)00045-6.